Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)

ClinicalTrials.gov ID: NCT03420014

Public ClinicalTrials.gov record NCT03420014. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Metastatic Leiomyosarcoma

Study identification

NCT ID: NCT03420014
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Philogen S.p.A.; Industry
Enrollment: 114 participants

Conditions and interventions

Conditions

Leiomyosarcoma

Interventions

Doxorubicin Drug
L19TNF plus doxorubicin Combination Product

Drug · Combination Product

Eligibility (public fields only)

Age range: 16 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 26, 2018
Primary completion: Nov 30, 2024
Completion: Nov 30, 2025
Last update posted: Oct 9, 2023

2018 – 2025

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Mayo Clinic Hospital	Phoenix	Arizona	85054	Recruiting
Sarcoma Oncology Research Center (SORC) Cancer Center of Southern California	Santa Monica	California	90403	Recruiting
Mayo Clinic Hospital	Jacksonville	Florida	32224	Recruiting
Mayo Clinic	Rochester	Minnesota	55905	Recruiting
Washington University	St Louis	Missouri	63110	Recruiting
Rutgers Cancer Institute of New Jersey 195 Little Albany Street New Brunswick, NJ 08901 Room 2031	New Brunswick	New Jersey	08901	Recruiting
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43202	Recruiting
Seattle Cancer Care Alliance 825 Eastlake Ave. E. Seattle, WA 98109 Mail Stop CE2-128	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03420014, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 9, 2023 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03420014 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →